Lindy G Durrant

Summary

Affiliation: University of Nottingham
Country: UK

Publications

  1. pmc Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy
    L G Durrant
    Academic Department of Clinical Oncology, Molecular Medical Sciences, City Hospital, University of Nottingham, Nottingham, UK
    Clin Exp Immunol 167:206-15. 2012
  2. pmc High avidity cytotoxic T lymphocytes can be selected into the memory pool but they are exquisitely sensitive to functional impairment
    Victoria A Brentville
    Scancell Holdings plc, Academic Department of Clinical Oncology, City Hospital Campus, University of Nottingham, Nottingham, United Kingdom
    PLoS ONE 7:e41112. 2012
  3. pmc The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer
    A Popple
    Academic Department of Clinical Oncology, Molecular Medical Sciences, City Hospital Campus, University of Nottingham, Nottingham NG5 1PB, UK
    Br J Cancer 106:1306-13. 2012
  4. pmc Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma
    K Pritchard-Jones
    Royal Marsden Hospital and Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 92:1358-65. 2005
  5. doi request reprint Glycans as targets for therapeutic antitumor antibodies
    Catherine Rabu
    Academic Department of Clinical Oncology, City Hospital Campus, University of Nottingham, Nottingham, NG5 1PB, UK
    Future Oncol 8:943-60. 2012
  6. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
  7. ncbi request reprint Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients
    L G Durrant
    CRC Academic Department of Clinical Oncology, City Hospital, Hucknall Road, NG5 1PB, Nottingham, Nottinghamshire, UK
    Cancer Immunol Immunother 52:638-42. 2003
  8. ncbi request reprint Immunization against tumor cell surface complement-regulatory proteins
    L G Durrant
    Academic Unit of Clinical Oncology, City Hospital, Nottingham, UK
    Curr Opin Investig Drugs 2:959-66. 2001
  9. ncbi request reprint Human anti-idiotypic antibodies can be good immunogens as they target FC receptors on antigen-presenting cells allowing efficient stimulation of both helper and cytotoxic T-cell responses
    L G Durrant
    CRC Academic Unit of Clinical Oncology, University of Nottingham, City Hospital, Nottingham, United Kingdom
    Int J Cancer 92:414-20. 2001
  10. ncbi request reprint A new anticancer glycolipid monoclonal antibody, SC104, which directly induces tumor cell apoptosis
    Lindy G Durrant
    Institute of Infections, Immunity, and Inflammation, Cancer Research UK Department of Clinical Oncology, University of Nottingham and Scancell Ltd, BioCity, Nottingham, United Kingdom
    Cancer Res 66:5901-9. 2006

Collaborators

Detail Information

Publications61

  1. pmc Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy
    L G Durrant
    Academic Department of Clinical Oncology, Molecular Medical Sciences, City Hospital, University of Nottingham, Nottingham, UK
    Clin Exp Immunol 167:206-15. 2012
    ..This has resulted in the development of a number of vaccines and monoclonal antibodies that are showing promising results in recent clinical trials...
  2. pmc High avidity cytotoxic T lymphocytes can be selected into the memory pool but they are exquisitely sensitive to functional impairment
    Victoria A Brentville
    Scancell Holdings plc, Academic Department of Clinical Oncology, City Hospital Campus, University of Nottingham, Nottingham, United Kingdom
    PLoS ONE 7:e41112. 2012
    ..This could contribute to failure of the immune system to control the growth of tumors and has implications for vaccination strategies and adoptive transfer of T cells...
  3. pmc The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer
    A Popple
    Academic Department of Clinical Oncology, Molecular Medical Sciences, City Hospital Campus, University of Nottingham, Nottingham NG5 1PB, UK
    Br J Cancer 106:1306-13. 2012
    ..The chemokine CXCL12 and its cognate receptor, CXCR4, have been implicated in numerous tumour types where expression promotes tumour growth, angiogenesis, metastasis and suppresses tumour immunity...
  4. pmc Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma
    K Pritchard-Jones
    Royal Marsden Hospital and Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 92:1358-65. 2005
    ..Future clinical trials incorporating immune stimulation strategies should include early introduction of vaccines during the highest risk period for relapse...
  5. doi request reprint Glycans as targets for therapeutic antitumor antibodies
    Catherine Rabu
    Academic Department of Clinical Oncology, City Hospital Campus, University of Nottingham, Nottingham, NG5 1PB, UK
    Future Oncol 8:943-60. 2012
    ..This article also presents various strategies used by different groups to develop mAbs against these naturally poorly immunogenic glycans...
  6. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
    ..Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer...
  7. ncbi request reprint Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients
    L G Durrant
    CRC Academic Department of Clinical Oncology, City Hospital, Hucknall Road, NG5 1PB, Nottingham, Nottinghamshire, UK
    Cancer Immunol Immunother 52:638-42. 2003
    ..However, it is a marker of aggression, as colorectal cancer patients whose tumours overexpress CD55 have a significantly reduced 7-year survival...
  8. ncbi request reprint Immunization against tumor cell surface complement-regulatory proteins
    L G Durrant
    Academic Unit of Clinical Oncology, City Hospital, Nottingham, UK
    Curr Opin Investig Drugs 2:959-66. 2001
    ....
  9. ncbi request reprint Human anti-idiotypic antibodies can be good immunogens as they target FC receptors on antigen-presenting cells allowing efficient stimulation of both helper and cytotoxic T-cell responses
    L G Durrant
    CRC Academic Unit of Clinical Oncology, University of Nottingham, City Hospital, Nottingham, United Kingdom
    Int J Cancer 92:414-20. 2001
    ..The immunogenicity of other anti-idiotypes may therefore be enhanced by human Fc targeting of antigen-presenting cells...
  10. ncbi request reprint A new anticancer glycolipid monoclonal antibody, SC104, which directly induces tumor cell apoptosis
    Lindy G Durrant
    Institute of Infections, Immunity, and Inflammation, Cancer Research UK Department of Clinical Oncology, University of Nottingham and Scancell Ltd, BioCity, Nottingham, United Kingdom
    Cancer Res 66:5901-9. 2006
    ..Furthermore, SC104 antibody shows additive killing with complement and 5-fluorouracil/leucovorin in vivo, suggesting a new therapeutic approach for this class of antibodies...
  11. ncbi request reprint Development of cancer vaccines to activate cytotoxic T lymphocytes
    L G Durrant
    University of Nottingham, Institute of Infections, Immunity and Inflammation, Department of Clinical Oncology, City Hospital, Hucknall Road, NG5 1PB, UK
    Expert Opin Biol Ther 5:555-63. 2005
    ..These approaches in combination with regimes, such as cytokine therapy, chemotherapy or radiotherapy, that modulate effector costimulatory expression on tumour targets may result in more effective second-generation cancer vaccines...
  12. doi request reprint Using monoclonal antibodies to stimulate antitumor cellular immunity
    Lindy G Durrant
    Academic Department of Clinical Oncology, University of Nottingham, City Hospital, Hucknall Road, Nottingham, NG5 1PB, UK
    Expert Rev Vaccines 10:1093-106. 2011
    ..Combinations of mAbs targeting tumor antigens to activated antigen-presenting cells and mAbs targeting costimulatory receptors may provide effective therapy for a broad range of tumors...
  13. doi request reprint Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer
    Jonathan A D Simpson
    Academic Department of Clinical Oncology, Institute of Immunology, Infections and Immunity, University of Nottingham, City Hospital Campus, Nottingham, UK
    Gut 59:926-33. 2010
    ..To evaluate immunosurveillance/editing in colorectal cancer...
  14. doi request reprint Vaccines as early therapeutic interventions for cancer therapy: neutralising the immunosuppressive tumour environment and increasing T cell avidity may lead to improved responses
    Lindy G Durrant
    Academic Department of Clinical Oncology, City Hospital, University of Nottingham, Hucknall Road, Nottingham NG5 1PB, UK
    Expert Opin Biol Ther 10:735-48. 2010
    ..This has led to the success of monoclonal antibody therapy and the recent approval of prophylactic vaccines that give excellent protection against cervical cancer. Provenge will shortly be the first therapeutic vaccine to be approved...
  15. pmc Upregulation of MICA on high-grade invasive operable breast carcinoma
    Zahra Madjd
    Academic Department of Clinical Oncology, Institute of Infections, Immunity and Inflammation, University of Nottingham, City Hospital, Nottingham, NG5 1PB, United Kingdom
    Cancer Immun 7:17. 2007
    ..Our results suggest that induced expression of MICA may be an indicator of poor prognosis in breast carcinoma and is indicative of a tumour environment that has undergone stresses such as apoptosis, necrosis, or hypoxia...
  16. ncbi request reprint A neoadjuvant/adjuvant randomized trial of colorectal cancer patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55
    Gustav J Ullenhag
    Academic Department of Clinical Oncology, Nottingham City Hospital, Nottingham, United Kingdom
    Clin Cancer Res 12:7389-96. 2006
    ..105AD7 is a human anti-idiotypic antibody mimicking CD55, a glycoprotein, which is more than expressed on colorectal cancer cells and protects them from attack by complement...
  17. ncbi request reprint Expression of the membrane complement regulatory protein CD59 (protectin) is associated with reduced survival in colorectal cancer patients
    Nicholas F S Watson
    Academic Department of Clinical Oncology, City Hospital, University of Nottingham, Hucknall Road, Nottingham, NG5 1PB, UK
    Cancer Immunol Immunother 55:973-80. 2006
    ..This study has identified CD59 expression as a marker of poor prognosis in colorectal cancer patients...
  18. doi request reprint Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies?
    Timothy J Duncan
    Academic and Clinical Department of Oncology, University of Nottingham, Nottingham, UK
    Clin Cancer Res 14:3030-5. 2008
    ..This study aims to establish the pattern of expression and effect on prognosis of VEGF in a large population of ovarian cancer patients and to potentially identify a cohort in whom antiangiogenic therapy is appropriate...
  19. doi request reprint Cytoplasmic p27 expression is an independent prognostic factor in ovarian cancer
    Timothy J Duncan
    Academic and Clinical Department of Oncology, University of Nottingham, Nottingham, UK
    Int J Gynecol Pathol 29:8-18. 2010
    ..These data support a novel role for p27 within the cytoplasm, possibly through effects on apoptosis, cellular motility, and drug resistance...
  20. doi request reprint DNA vaccination with T-cell epitopes encoded within Ab molecules induces high-avidity anti-tumor CD8+ T cells
    Victoria A Pudney
    Scancell Limited, Academic Department of Clinical Oncology, University of Nottingham, City Hospital, Nottingham, UK
    Eur J Immunol 40:899-910. 2010
    ..High-avidity responses were capable of efficient anti-tumor activity in vitro and in vivo. This study demonstrates a vaccine strategy to generate high-avidity CTL responses that can be used in anti-tumor and anti-viral vaccine settings...
  21. ncbi request reprint Complement decay accelerating factor (DAF)/CD55 in cancer
    Ian Spendlove
    CR UK Academic Department of Clinical Oncology, Institute of Infections Immunity and Inflammation, The University of Nottingham, NG5 1PB, Nottingham, UK
    Cancer Immunol Immunother 55:987-95. 2006
    ..We will also provide some data providing a potential mechanism by which soluble CD55 can inhibit T-cell function and discuss some of the implications of this data...
  22. pmc The role of MUC1 and MUC3 in the biology and prognosis of colorectal cancer
    Timothy J Duncan
    Academic Department of Clinical Oncology, Institute of Immunology, Infections and Immunity, University of Nottingham, City Hospital, Nottingham, UK
    World J Surg Oncol 5:31. 2007
    ..We propose that tumours lacking expression of MUC1 and MUC3 will be more likely to metastasise, due to previously observed loss of cell-cell adhesion, and this will therefore lead to more aggressive cancers with poorer prognosis...
  23. ncbi request reprint Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients
    Nicholas F S Watson
    Academic Department of Clinical Oncology, University of Nottingham, City Hospital, Nottingham, United Kingdom
    Int J Cancer 118:1445-52. 2006
    ..In contrast, patients with high expression of MICA may be candidates for the antibody therapies, as they should be susceptible to NK killing by antibody dependent cellular cytotoxicity...
  24. ncbi request reprint The use of reverse immunology to identify HLA-A2 binding epitopes in Tie-2
    Judith M Ramage
    Academic Unit of Clinical Oncology, Nottingham University, Hucknall Road, City Hospital, NG5 1PB, Nottingham, UK
    Cancer Immunol Immunother 55:1004-10. 2006
    ..Caution should therefore be employed in the use of both reverse immunology and anchor modification of CTL epitopes in the identification of CTL epitopes for cancer vaccines...
  25. ncbi request reprint Cytoplasmic expression of p27(kip1) is associated with a favourable prognosis in colorectal cancer patients
    Nicholas F S Watson
    Section of Gastrointestinal Surgery, University of Nottingham, E Floor, West Block, Queens Medical Centre, Derby Road, Nottingham, NG7 2UH, United Kingdom
    World J Gastroenterol 12:6299-304. 2006
    ..To evaluate the prognostic significance of p27(kip1) in colorectal cancer patients...
  26. ncbi request reprint Do poor-prognosis breast tumours express membrane cofactor proteins (CD46)?
    Zahra Madjd
    CRC Academic Department of Clinical Oncology, Nottingham City Hospital, Hucknall Road, Nottingham, NG5 1PB, UK
    Cancer Immunol Immunother 54:149-56. 2005
    ..This may suggest that CD46 alone can protect from complement lysis but that loss of CD55 and CD59 are associated with other roles in immune regulation...
  27. ncbi request reprint Costimulation via CD55 on human CD4+ T cells mediated by CD97
    Melania Capasso
    Academic Department of Clinical Oncology, Institute of Infection, Immunity and Inflammation, University of Nottingham, City Hospital, Nottingham NG5 1PB, United Kingdom
    J Immunol 177:1070-7. 2006
    ..Our results support a multifaceted role for CD55 in human T cell activation, constituting a further link between innate and adaptive immunity...
  28. ncbi request reprint Loss of CD55 is associated with aggressive breast tumors
    Zahra Madjd
    Cancer Research UK Academic Unit of Clinical Oncology, University of Nottingham, City Hospital, Nottingham, United Kingdom
    Clin Cancer Res 10:2797-803. 2004
    ..CD55 is overexpressed on some tumor cell lines, and in colorectal carcinomas, it has been shown to be an indicator of poor prognostic...
  29. pmc High expression of Lewis y/b antigens is associated with decreased survival in lymph node negative breast carcinomas
    Zahra Madjd
    Academic Department of Clinical Oncology, Institute of Infections Immunity and Inflammation, University of Nottingham, City Hospital, Nottingham, UK
    Breast Cancer Res 7:R780-7. 2005
    ..The SC101 mAb is a unique Lewisy/b binding antibody that binds to native and extended Lewisy and Lewisb haptens, displaying no cross reactivity with H type 1, H type 2, Lewisx or normal blood group antigens...
  30. ncbi request reprint Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis
    Nicholas F S Watson
    Academic Department of Clinical Oncology, University of Nottingham, City Hospital, Nottingham, United Kingdom
    Int J Cancer 118:6-10. 2006
    ..The existence of these poor prognosis tumors, which may avoid both NK- and T-cell-mediated immune surveillance, has important implications for the design of immunotherapeutic strategies in colorectal cancer...
  31. ncbi request reprint ULBP2 and RAET1E NKG2D ligands are independent predictors of poor prognosis in ovarian cancer patients
    Roger W McGilvray
    Academic Division of Clinical Oncology, University of Nottingham, City Hospital Campus, Nottingham, United Kingdom
    Int J Cancer 127:1412-20. 2010
    ..001), presence of residual disease (p = 0.003), ULBP2 (p = 0.042) and RAET1E (p = 0.030)...
  32. ncbi request reprint Identification of an HLA-A*0201 cytotoxic T lymphocyte epitope specific to the endothelial antigen Tie-2
    Judith M Ramage
    Cancer Research UK, Academic Unit of Clinical Oncology, University of Nottingham, City Hospital, Nottingham, United Kingdom
    Int J Cancer 110:245-50. 2004
    ..Our study demonstrates that it is possible to break tolerance to the endothelial antigen Tie-2, suggesting that it may be feasible to design a vaccine to activate CTLs to kill endothelial cells overexpressing Tie-2...
  33. ncbi request reprint A novel CEA vaccine stimulates T cell proliferation, gammaIFN secretion and CEA specific CTL responses
    T Parsons
    CRC Academic Department of Clinical Oncology, University of Nottingham, City Hospital, Hucknall Road, Nottingham NG5 1PB, UK
    Vaccine 22:3487-94. 2004
    ..Furthermore, the CTLs killed tumour cells expressing CEA suggesting that this deimmunised antibody could be a useful vaccine for solid tumours...
  34. ncbi request reprint Loss of IFN gamma receptor is an independent prognostic factor in ovarian cancer
    Timothy J Duncan
    Academic and Clinical Department of Oncology, University of Nottingham, Nottingham, UK
    Clin Cancer Res 13:4139-45. 2007
    ..This hypothesis would support the theory of immunoediting in ovarian cancer...
  35. pmc NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting
    Roger W McGilvray
    Academic Division of Clinical Oncology, University of Nottingham, City Hospital Campus, Section of Gastrointestinal Surgery, Queen s Medical Centre, John Van Geest Research Centre, Nottingham Trent University, Clifton Campus, Nottingham, United Kingdom
    Clin Cancer Res 15:6993-7002. 2009
    ..The role of NKG2D ligands is thought to be important in carcinogenesis but its prognostic effect has not been investigated in such a large cohort...
  36. ncbi request reprint 105Ad7 cancer vaccine stimulates anti-tumour helper and cytotoxic T-cell responses in colorectal cancer patients but repeated immunisations are required to maintain these responses
    L G Durrant
    CRC Department of Clinical Oncology, University of Nottingham, Nottingham, UK
    Int J Cancer 85:87-92. 2000
    ..Our results suggest that 105AD7 can stimulate CD4 and CD8 responses in patients with the appropriate haplotype. However, it may be necessary to continue to immunise, since few patients produce a sustained memory response...
  37. doi request reprint T-cell responses in osteosarcoma patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55
    G J Ullenhag
    Academic Department of Clinical Oncology, Nottingham City Hospital, Nottingham, NG5 1PB, UK
    Clin Immunol 128:148-54. 2008
    ..Clinical responses and induction of immune responses to both the anti-idiotype and the native CD55 antigen support the use of CD55 as a target in cancer treatment...
  38. doi request reprint CD55 costimulation induces differentiation of a discrete T regulatory type 1 cell population with a stable phenotype
    Ruhcha V Sutavani
    Academic Department of Clinical Oncology, University of Nottingham, City Hospital, Nottingham NG5 1PB, United Kingdom
    J Immunol 191:5895-903. 2013
    ....
  39. ncbi request reprint A neoadjuvant clinical trial in colorectal cancer patients of the human anti-idiotypic antibody 105AD7, which mimics CD55
    L G Durrant
    Cancer Research Campaign Academic Unit of Clinical Oncology, University of Nottingham, United Kingdom
    Clin Cancer Res 6:422-30. 2000
    ..The study confirms that immunization with a human anti-idiotypic antibody results in immune responses in 83% of patients with a permissive haplotype...
  40. pmc Antibodies designed as effective cancer vaccines
    R L Metheringham
    Scancell Limited, Department of Clinical Oncology, University of Nottingham, Nottingham, UK
    MAbs 1:71-85. 2009
    ....
  41. pmc Calpain system protein expression in carcinomas of the pancreas, bile duct and ampulla
    Sarah J Storr
    Academic Oncology, University of Nottingham, School of Molecular Medical Sciences, Nottingham University Hospitals NHS Trust, City Hospital Campus, Nottingham, UK
    BMC Cancer 12:511. 2012
    ..Pancreatic cancer, including cancer of the ampulla of Vater and bile duct, is very aggressive and has a poor five year survival rate; improved methods of patient stratification are required...
  42. ncbi request reprint Current concepts in immunotherapy for the treatment of colorectal cancer
    A Indar
    Division of Surgery, Queens Medical Centre, Nottingham, UK
    J R Coll Surg Edinb 47:458-74. 2002
    ....
  43. ncbi request reprint The role of CD55 in protecting the tumour environment from complement attack
    J Morgan
    The University of Nottingham, Cancer Research UK, Nottingham, UK
    Tissue Antigens 60:213-23. 2002
    ..This suggests that it may have a further role to play in protecting cells during inflammation and invasion...
  44. ncbi request reprint Decay accelerating factor (CD55): a target for cancer vaccines?
    I Spendlove
    Cancer Research Campaign Academic Unit of Clinical Oncology, University of Nottingham, City Hospital, United Kingdom
    Cancer Res 59:2282-6. 1999
    ..It is therefore a very intriguing target, because absence of the molecule makes the tumor cells susceptible to complement, whereas protective overexpression results in the antigen being a target for T-cell immunotherapy...
  45. ncbi request reprint A therapeutic human anti-idiotypic antibody mimics CD55 in three distinct regions
    L Spendlove
    CRC Academic Unit of Clinical Oncology, University of Nottingham, City Hospital, GB
    Eur J Immunol 30:2944-53. 2000
    ..These findings help identify the mechanism by which a human anti-idiotypic antibody is able to mimic a tumor-associated antigen and stimulate anti-tumor B and T cell responses...
  46. pmc Therapeutic targeting of Lewis(y) and Lewis(b) with a novel monoclonal antibody 692/29
    Philip Noble
    Academic Department of Clinical Oncology, City Hospital Campus, University of Nottingham, Nottingham, UK
    PLoS ONE 8:e54892. 2013
    ..We then assessed the in vivo therapeutic effect of 692/29 using xenograft models...
  47. pmc Enhanced recognition of human colorectal tumour cells using combinations of monoclonal antibodies
    L G Durrant
    Cancer Research Campaign Laboratory, University of Nottingham, UK
    Br J Cancer 60:855-60. 1989
    ..Combinations of monoclonal antibodies which recognise a high percentage of tumours are likely to be necessary for monoclonal antibody drug targeting to prevent tumour recurrence and/or metastases...
  48. ncbi request reprint Cancer vaccines entering Phase III clinical trials
    L G Durrant
    CRUK Department of Clinical Oncology, University of Nottingham, City Hospital, Nottingham, NG5 1PB, UK
    Expert Opin Emerg Drugs 8:489-500. 2003
    ..This review outlines some of the approaches that have led to some of these vaccines entering Phase III clinical trials, discusses their modes of action and reports on their current status in trial...
  49. pmc CD55 is over-expressed in the tumour environment
    L Li
    CRC Academic Unit of Clinical Oncology, University of Nottingham, City Hospital, Hucknall Road, Nottingham, NG5 1PB, UK
    Br J Cancer 84:80-6. 2001
    ..Although it remains unclear why CD55 is upregulated in the tumour environment its high level of expression on tumour cells and associated endothelium may explain why it is a good target for both imaging and immunotherapy...
  50. doi request reprint CD24 shows early upregulation and nuclear expression but is not a prognostic marker in colorectal cancer
    M A H Ahmed
    Division of Pathology, School of Molecular Medical Sciences, Queen s Medical Centre Campus, University of Nottingham, Nottingham NG7 2UH, UK
    J Clin Pathol 62:1117-22. 2009
    ..Recently it has been reported to be upregulated and of prognostic importance in colorectal tumours. The study aims to study the prognostic value of CD24 in a large series of colorectal cancer (CRC)...
  51. ncbi request reprint Loss of CD59 expression in breast tumours correlates with poor survival
    Z Madjd
    CRC Academic Unit of Clinical Oncology, University of Nottingham, City Hospital, Hucknall Road, Nottingham, NG5 1PB, UK
    J Pathol 200:633-9. 2003
    ..These findings indicate that loss of CD59 may offer a selective advantage for breast cancers, resulting in more aggressive tumours and conferring a poor prognosis for patients...
  52. pmc Sensitivity of newly established colorectal cell lines to cytotoxic drugs and monoclonal antibody drug conjugates
    L G Durrant
    Cancer Research Campaign Laboratories, University of Nottingham, University Park, UK
    Br J Cancer 56:722-6. 1987
    ..This is the first report to show that newly established cell lines that are resistant to classical chemotherapeutic agents are rendered sensitive when the drug enters the cell as a drug monoclonal antibody carrier...
  53. pmc Development of an ELISA to detect early local relapse of colorectal cancer
    L G Durrant
    Cancer Research Campaign Laboratory, University of Nottingham, UK
    Br J Cancer 60:533-7. 1989
    ..Recognition of antigens bearing the Y hapten may therefore be useful in detecting early local relapse of colorectal cancer when a second operation to excise the recurrence may be possible...
  54. pmc Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer
    C A Maxwell Armstrong
    Division of Gastrointestinal Surgery, University Hospital, Queens Medical Centre, Nottingham, NG7 2UH, UK
    Br J Cancer 84:1443-6. 2001
    ..The reasons for lack of efficacy are unclear, but may reflect the high tumour burden in the patient population, and poor compliance with immunization. Further vaccine studies should concentrate on patients with minimal residual disease...
  55. ncbi request reprint Comparison of the immune response to a self antigen after DNA immunisation of HLA*A201/H-2Kb and HHD transgenic mice
    Judith M Ramage
    CR UK Academic Department of Clinical Oncology, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK
    Vaccine 22:1728-31. 2004
    ..HHD mice are therefore useful for studying immunisation strategies for inducing and maintaining CD8 responses to over-expressed self antigens...
  56. pmc Quantitation of MHC antigen expression on colorectal tumours and its association with tumour progression
    L G Durrant
    Cancer Research Campaign Laboratories, University of Nottingham, UK
    Br J Cancer 56:425-32. 1987
    ..If there is a correlation between in vitro and in vivo growth perhaps tumours are maintained and seeded by MHC antigen negative cells...
  57. ncbi request reprint The effect of the E2 prostaglandin enprostil, and the somatostatin analogue SMS 201 995, on the growth of a human gastric cell line, MKN45G
    S A Watson
    Cancer Research Campaign Laboratories, University of Nottingham, UK
    Int J Cancer 45:90-4. 1990
    ..Gastrin release by MKN45G was not affected by SMS 201 995 in vitro, thus its effect may not be mediated directly via gastrin, requiring interaction between other hormones or growth factors in the in vivo situation...
  58. pmc Co-stimulation of gastrointestinal tumour cell growth by gastrin, transforming growth factor alpha and insulin like growth factor-I
    L G Durrant
    Cancer Research Campaign Laboratories, University of Nottingham, UK
    Br J Cancer 63:67-70. 1991
    ..Furthermore the effects of the growth factors were additive. Each growth factor also increased the response of the cells to gastrin, but a combination of both growth factors and gastrin did not further increase growth...
  59. doi request reprint Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients?
    Ekaterina S Jordanova
    Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
    Clin Cancer Res 14:2028-35. 2008
    ..To investigate the effect of intraepithelial tumor-infiltrating lymphocytes (ieTIL) and their ligands expressed by cervical tumor cells on the outcome of cervical cancer patients...
  60. ncbi request reprint Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients
    Gustave J Ullenhag
    Section of Gastrointestinal Surgery, University Hospital Nottingham, United Kingdom
    Clin Cancer Res 13:5070-5. 2007
    ..We sought to determine the prognostic value of the clinically most relevant members of this pathway in colorectal cancer patients...
  61. ncbi request reprint Total loss of MHC class I is an independent indicator of good prognosis in breast cancer
    Zahra Madjd
    Cancer Research UK Academic Unit of Clinical Oncology, Nottingham City Hospital, United Kingdom
    Int J Cancer 117:248-55. 2005
    ..001), tumour grade (p = 0.005) and intensity of MHC Class I light and heavy chains expression were shown to be independent prognostic factors predictive of overall survival (p-values HC10 = 0.047 and beta2m = 0.018)...